Bing Hu1, Bo Sun2, Dao-Jian Gao2, Jun Wu2, Xin Ye2, Ming-Xing Xia2, Tian-Tian Wang2. 1. Department of Gastroenterology and Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, 200438, China. drhubing@aliyun.com. 2. Department of Gastroenterology and Endoscopy, Eastern Hepatobiliary Hospital, Second Military Medical University, Shanghai, 200438, China.
Abstract
BACKGROUND: Endoscopic ablation of duodenal ampullary malignancy has not been fully assessed. AIMS: The study aimed to evaluate the efficacy and safety of Endoscopic retrograde cholangiopancreatograpy (ERCP)-guided radiofrequency ablation (RFA) for inoperable ampullary cancer. METHODS: Patients with inoperable ampullary cancer underwent ERCP-guided RFA from January 2012 to August 2017. RF energy (7-10 W) was delivered using bipolar RFA electrodes under endoscopic guidance. RFAs were repeated every 1-3 months until visible tumor was eliminated. All patients were followed up till June 2018, during which any biliary event was noted and managed endoscopically. RESULTS: Twenty-three patients underwent a median of two RFA sessions (range 1-6) at a median interval of 56 (range 35-90) days. Among 18 (78.3%) patients who received endoscopic re-evaluations, nine patients showed no remaining lesion and nine showed more than 50% tumor size reduction. During a median follow-up duration of 517 days (range 60-1836 days), eight (34.8%) patients required endoscopic re-interventions. The re-intervention rate at 6 months after RFA was 36.8%. Twelve patients were alive, among whom six required no biliary stenting. The accumulative mean survival was 1081 (95% CI 757.8-1404.0) days. RFA-related adverse events occurred in four cases (7.7%) including mild pancreatitis (1), bleeding (1), and late distal biliary stenosis (2). CONCLUSION: This pilot study shows that ERCP-guided RFA is safe to use and able to reduce tumor volume and re-interventions in patients with inoperable ampullary cancer.
BACKGROUND: Endoscopic ablation of duodenal ampullary malignancy has not been fully assessed. AIMS: The study aimed to evaluate the efficacy and safety of Endoscopic retrograde cholangiopancreatograpy (ERCP)-guided radiofrequency ablation (RFA) for inoperable ampullary cancer. METHODS:Patients with inoperable ampullary cancer underwent ERCP-guided RFA from January 2012 to August 2017. RF energy (7-10 W) was delivered using bipolar RFA electrodes under endoscopic guidance. RFAs were repeated every 1-3 months until visible tumor was eliminated. All patients were followed up till June 2018, during which any biliary event was noted and managed endoscopically. RESULTS: Twenty-three patients underwent a median of two RFA sessions (range 1-6) at a median interval of 56 (range 35-90) days. Among 18 (78.3%) patients who received endoscopic re-evaluations, nine patients showed no remaining lesion and nine showed more than 50% tumor size reduction. During a median follow-up duration of 517 days (range 60-1836 days), eight (34.8%) patients required endoscopic re-interventions. The re-intervention rate at 6 months after RFA was 36.8%. Twelve patients were alive, among whom six required no biliary stenting. The accumulative mean survival was 1081 (95% CI 757.8-1404.0) days. RFA-related adverse events occurred in four cases (7.7%) including mild pancreatitis (1), bleeding (1), and late distal biliary stenosis (2). CONCLUSION: This pilot study shows that ERCP-guided RFA is safe to use and able to reduce tumor volume and re-interventions in patients with inoperable ampullary cancer.
Entities:
Keywords:
Ampulla of Vater; Bile duct neoplasms; Endoscopic retrograde cholangiopancreatograpy (ERCP); Radiofrequency ablation
Authors: Wim Laleman; Schalk van der Merwe; Len Verbeke; Dirk Vanbeckevoort; Raymond Aerts; Hans Prenen; Eric Van Cutsem; Chris Verslype Journal: Endoscopy Date: 2017-07-21 Impact factor: 10.093
Authors: Su Bum Park; Hyung Wook Kim; Dae Hwan Kang; Cheol Woong Choi; Je Ho Ryu; Chong Woo Chu; Soo Yong Lee; Young Il Jeong; Hye Ju Yeo; Eun Jung Kim Journal: Dig Dis Sci Date: 2011-09-23 Impact factor: 3.199
Authors: A Schmidt; M Bloechinger; A Weber; J Siveke; S von Delius; C Prinz; W Schmitt; R M Schmid; B Neu Journal: United European Gastroenterol J Date: 2016-02-03 Impact factor: 4.623
Authors: Tarun Rustagi; Shayan Irani; D Nageshwar Reddy; Barham K Abu Dayyeh; Todd H Baron; Christopher J Gostout; Michael J Levy; John Martin; Bret T Petersen; Andrew Ross; Mark D Topazian Journal: Gastrointest Endosc Date: 2016-11-17 Impact factor: 9.427
Authors: Abdurrahman Kadayifci; Mustafa Atar; David G Forcione; Brenna W Casey; Peter B Kelsey; William R Brugge Journal: Endoscopy Date: 2016-10-07 Impact factor: 10.093
Authors: Reem Z Sharaiha; Nikola Natov; Kati S Glockenberg; Jessica Widmer; Monica Gaidhane; Michel Kahaleh Journal: Dig Dis Sci Date: 2014-07-18 Impact factor: 3.199